(Q36568461)

15 August 2017

1 reference

title

The mighty mouse: genetically engineered mouse models in cancer drug development (English)

1 reference

15 August 2017

1

1 reference

15 August 2017

2

Ronald A Depinho

1 reference

15 August 2017

18 August 2006

1 reference

Nature Reviews Drug Discovery

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

741-754

1 reference

15 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2110

15 August 2017

0 references

cites work

Aberrant expression of p53 gene product in malignant melanoma

1 reference

Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity

21 January 2018

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

Can the pharmaceutical industry reduce attrition rates?

31 March 2020

1 reference

Are large clinical trials in rapidly lethal diseases usually unethical?

31 March 2020

1 reference

Responses and toxic deaths in phase I clinical trials

31 March 2020

1 reference

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

31 March 2020

1 reference

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

31 March 2020

1 reference

Stem cells, cancer, and cancer stem cells

31 March 2020

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

31 March 2020

1 reference

Differentiation and reversal of malignant changes in colon cancer through PPARgamma

31 March 2020

1 reference

A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer

31 March 2020

1 reference

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

31 March 2020

1 reference

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

31 March 2020

1 reference

Angiostatin induces and sustains dormancy of human primary tumors in mice

31 March 2020

1 reference

Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression

31 March 2020

1 reference

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer

31 March 2020

1 reference

First clinical trials of endostatin yield lukewarm results

31 March 2020

1 reference

In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna

31 March 2020

1 reference

Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors

31 March 2020

1 reference

Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.

31 March 2020

1 reference

Contributions of human tumor xenografts to anticancer drug development

31 March 2020

1 reference

Animal models for studying the action of topoisomerase I targeted drugs

31 March 2020

1 reference

Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development

31 March 2020

1 reference

Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children

31 March 2020

1 reference

The minimal set of genetic alterations required for conversion of primary human fibroblasts to cancer cells in the subrenal capsule assay

31 March 2020

1 reference

Tumorigenic study on hepatocytes coexpressing SV40 with Ras.

31 March 2020

1 reference

Epidermal growth factor receptor and Ink4a/Arf

31 March 2020

1 reference

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

31 March 2020

1 reference

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma

31 March 2020

1 reference

Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse

31 March 2020

1 reference

Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo.

31 March 2020

1 reference

Cooperative effects of INK4a and ras in melanoma susceptibility in vivo

31 March 2020

1 reference

Dual inactivation of RB and p53 pathways in RAS-induced melanomas

31 March 2020

1 reference

Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma

31 March 2020

1 reference

Absence of p53 gene mutations in cutaneous melanoma

31 March 2020

1 reference

A cell cycle regulator potentially involved in genesis of many tumor types

31 March 2020

1 reference

Germline p16 mutations in familial melanoma

31 March 2020

1 reference

Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition

31 March 2020

1 reference

Scaling down imaging: molecular mapping of cancer in mice

31 March 2020

1 reference

Fluorescence molecular imaging of small animal tumor models.

31 March 2020

1 reference

Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity

31 March 2020

1 reference

Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes

31 March 2020

1 reference

Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice.

31 March 2020

1 reference

Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors

31 March 2020

1 reference

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes

31 March 2020

1 reference

Transgenic models of tumor development.

31 March 2020

1 reference

Effects of an Rb mutation in the mouse

31 March 2020

1 reference

Tumor spectrum analysis in p53-mutant mice

31 March 2020

1 reference

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

31 March 2020

1 reference

Cancer modeling in the modern era: progress and challenges

31 March 2020

1 reference

Essential role for oncogenic Ras in tumour maintenance

31 March 2020

1 reference

Reversible tumorigenesis by MYC in hematopoietic lineages

31 March 2020

1 reference

c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations

31 March 2020

1 reference

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

31 March 2020

1 reference

Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes

31 March 2020

1 reference

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

31 March 2020

1 reference

Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation

31 March 2020

1 reference

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer

31 March 2020

1 reference

Cdk2 knockout mice are viable

31 March 2020

1 reference

Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.

31 March 2020

1 reference

Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1).

31 March 2020

1 reference

Cdc2-cyclin E complexes regulate the G1/S phase transition

31 March 2020

1 reference

Requirement for CDK4 kinase function in breast cancer

31 March 2020

1 reference

Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis

31 March 2020

1 reference

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

31 March 2020

1 reference

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

31 March 2020

1 reference

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

31 March 2020

1 reference

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

31 March 2020

1 reference

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

31 March 2020

1 reference

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

31 March 2020

1 reference

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

31 March 2020

1 reference

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

31 March 2020

1 reference

Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf

31 March 2020

1 reference

A mouse model of human oral-esophageal cancer

31 March 2020

1 reference

Suppression of intestinal neoplasia by DNA hypomethylation.

31 March 2020

1 reference

Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer.

31 March 2020

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

31 March 2020

1 reference

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

31 March 2020

1 reference

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Reporter mice and drug discovery and development

31 March 2020

1 reference

ErbB2 is essential in the prevention of dilated cardiomyopathy.

31 March 2020

1 reference

Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice

31 March 2020

1 reference

Managing innovation: university-industry partnerships and the licensing of the Harvard mouse

31 March 2020

1 reference

Intellectual property. DuPont ups ante on use of Harvard's OncoMouse

31 March 2020

1 reference

Canada stops Harvard's oncomouse in its tracks

31 March 2020

1 reference

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

31 March 2020

1 reference

Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia

31 March 2020

1 reference

The Occurrence of a Dominant Spotting Mutation in the House Mouse

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2110

1 reference

PubMed ID

16915232

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

16915232